Traws Pharma

Q2 FY2026 EarningsQ2 FY26 performance was mixed against consensus: GAAP EPS of -$0.16 beat the -$0.3350 expectation, while EBIT loss of -$3.18M was narrower than the expected -$5.40M. Revenue was in-line at zero, following the termination of the Symbio license agreement. While the net loss narrowed due to a $1.4M legacy liability reversal, significant clinical setbacks emerged, including an FDA clinical hold on tivoxavir marboxil and a deferred UK challenge study, raising concerns over development timelines despite the earnings beat.